[1] | Acosta-Jamett G, Hernández FA, Castro N, et al. Prevalence rate and risk factors of human cystic echinococcosis: a cross-sectional, community-based, abdominal ultrasound study in rural and urban north-central Chile[J]. PLoS Negl Trop Dis, 2022, 16(3): e0010280. | [2] | Wang LY, Qin M, Liu ZH, et al. Prevalence and spatial distribution characteristics of human echinococcosis in China[J]. PLoS Negl Trop Dis, 2021, 15(12): e0009996. | [3] | Xu K, Wang ZX, Fan HN, et al. Hepatic echinococcosis misdiagnosed as liver cancer: a case report[J]. Chin J ParasitolParasit Dis, 2021, 39(3) :717-719. (in Chinese) | | (徐凯, 王志鑫, 樊海宁, 等. 肝棘球蚴病误诊肝癌1例报告[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(3): 717-719.) | [4] | Kalifu B, Meng Y, Maimaitinijiati Y, et al. Radical resection of hepatic polycystic echinococcosis complicated with hepatocellular carcinoma: a case report[J]. World J Clin Cases, 2021, 9(3): 659-665. | [5] | (Kazuaki, Ohtsubo. Glycosylation in cellular mechanisms of health and disease[J]. Cell, 2006, 126(5): 855-867. | [6] | Rudd PM, Elliott T, Cresswell P, et al. Glycosylation and the immune system[J]. Science, 2001, 291(5512): 2370-2376. | [7] | Bagdonaite I, Wandall HH. Global aspects of viral glycosylation[J]. Glycobiology, 2018, 28(7): 443-467. | [8] | Narimatsu Y, Büll C, Chen YH, et al. Genetic glycoengineering in mammalian cells[J]. J Biol Chem, 2021, 296: 100448. | [9] | Liu D, Li QH, Zhang XY, et al. Systematic review: immunoglobulin G N-glycans as next-generation diagnostic biomarkers for common chronic diseases[J]. OMICS, 2019, 23(12): 607-614. | [10] | Pincetic A, Bournazos S, Dilillo DJ, et al. Type I and type II Fc receptors regulate innate and adaptive immunity[J]. Nat Immunol, 2014, 15(8): 707-716. | [11] | Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?[J]. Nat Rev Immunol, 2013, 13(3): 176-189. | [12] | Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(1): 188464. | [13] | Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications[J]. Nat Rev Cancer, 2015, 15(9): 540-555. | [14] | Plomp R, Bondt A, de Haan N, et al. Recent advances in clinical glycoproteomics of immunoglobulins[J]. Mol Cell Proteomics, 2016, 15(7): 2217-2228. | [15] | Qin WJ, Pei H, Qin RH, et al. Alteration of serum IgG galactosylation as a potential biomarker for diagnosis of neuroblastoma[J]. J Cancer, 2018, 9(5): 906-913. | [16] | Harvey DJ. Electrospray mass spectrometry and fragmentation of N-linked carbohydrates derivatized at the reducing terminus[J]. J Am Soc Mass Spectrom, 2000, 11(10): 900-915. | [17] | Keser T, Pavi? T, Lauc G, et al. Comparison of 2-aminobenzamide, procainamide and RapiFluor-MS as derivatizing agents for high-throughput HILIC-UPLC-FLR-MS N-glycan analysis[J]. Front Chem, 2018, 6: 324. | [18] | Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease[J]. Lab Invest, 2007, 87(9): 851-857. | [19] | Zhang Y, Wang RH, Feng Y, et al. The role of sialyltransferases in gynecological malignant tumors[J]. Life Sci, 2020, 263: 118670. | [20] | Bhide GP, Colley KJ. Sialylation of N-glycans: mechanism, cellular compartmentalization and function[J]. Histochem Cell Biol, 2017, 147(2): 149-174. | [21] | Pietrobono S, Stecca B. Aberrant sialylation in cancer: biomarker and potential target for therapeutic intervention?[J]. Cancers, 2021, 13(9): 2014. | [22] | Ou LL, He XZ, Liu NH, et al. Sialylation of FGFR1 by ST6Gal?Ⅰ overexpression contributes to ovarian cancer cell migration and chemoresistance[J]. Mol Med Rep, 2020, 21(3): 1449-1460. | [23] | Wang ZH, Geng ZH, Shao WW, et al. Cancer-derived sialylated IgG promotes tumor immune escape by binding to siglecs on effector T cells[J]. Cell Mol Immunol, 2020, 17(11): 1148-1162. | [24] | Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases[J]. Cell Immunol, 2018, 333: 65-79. | [25] | Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation[J]. Science, 2006, 313(5787): 670-673. | [26] | Quast I, Keller CW, Maurer MA, et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity[J]. J Clin Invest, 2015, 125(11): 4160-4170. |
|